Domů › Rakovina močového měchýře › Massachusetts › Boston
Klinické studie Rakovina močového měchýře v Boston, MA
26 studií pro Rakovina močového měchýře hledá účastníky v lokalitách v Boston a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Probíhá náborFáze 3
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Probíhá náborFáze 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Probíhá náborFáze 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Probíhá náborFáze 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Probíhá náborFáze 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
Probíhá náborVítáni zdraví dobrovolníci
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Probíhá náborFáze 3
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Probíhá náborFáze 3
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Probíhá nábor
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Probíhá náborFáze 2
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Probíhá náborFáze 2
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Probíhá náborFáze 3
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Probíhá náborFáze 1/2
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Probíhá náborFáze 2/3
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Probíhá náborFáze 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Probíhá náborFáze 3
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- a dalších 2
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Probíhá náborObservační studie
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Probíhá nábor
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
Probíhá náborFáze 1/2
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Probíhá nábor
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Probíhá náborFáze 3
- Brigham and Women's Hospital, Boston
Studie Rakovina močového měchýře v jiných městech
- New York City, NY35 studií
- Nashville, TN31 studií
- Houston, TX31 studií
- Dallas, TX27 studií
- Washington, DC26 studií
- Los Angeles, CA24 studií
- Baltimore, MD24 studií
- St. Louis, MO22 studií
- Philadelphia, PA21 studií
- Seattle, WA21 studií
- Edison, NJ21 studií
- Chicago, IL21 studií
Další studie v Boston
- Rakovina prsu111 studií
- Nemalobuněčný plicní karcinom90 studií
- Rakovina (všechny typy)86 studií
- Kolorektální karcinom63 studií
- Metastatický karcinom63 studií
- Rakovina plic62 studií
- Rakovina vaječníků61 studií
- Rakovina prostaty59 studií
- Deprese52 studií
- Rakovina endometria50 studií
- Srdeční selhání44 studií
- Akutní myeloidní leukemie44 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.